The Association of Community Pharmacists of Nigeria (ACPN) has threatened legal action against the Chairman of the Edo State Consumer Protection Committee, Osaro Culture Iyamu, unless he provides evidence to support his reported claim that Camosunate is banned in Nigeria.
The association gave Iyamu 24 hours to produce an authentic regulatory document from the National Agency for Food and Drug Administration and Control (NAFDAC) confirming the alleged ban or publicly retract the statement and apologise.
In a statement, ACPN described the reported declaration as misleading, warning against what it called regulatory overreach and unsubstantiated claims about pharmaceutical products.
Start tomorrow informed
Save your place for the morning brief. We’ll start emailing when delivery goes live.
Free. Confirm by email. Unsubscribe anytime.
The association said its verification of NAFDAC's official Greenbook showed that Camosunate Children Powder, with registration number 04-7908, was an actively registered medicinal product.
It identified Front Pharmaceuticals PLC as the manufacturer and Geneith Pharmaceuticals Limited as the marketing company.
According to ACPN, NAFDAC approved the product's registration on November 26, 2025, with validity extending to November 25, 2030.
Describing the information as an official regulatory record, the association challenged Iyamu to produce a valid NAFDAC prohibition, suspension, withdrawal or cancellation notice covering the specific formulation he reportedly declared banned.
ACPN warned that failure to provide such evidence within the stipulated period would prompt it to demand a public retraction and apology.
It also threatened to pursue legal remedies over what it described as potentially false, damaging and unjustified public statements concerning registered medicines and pharmacy practitioners.
The association, however, acknowledged the importance of efforts to eliminate counterfeit, adulterated, substandard and expired medicines from the Nigerian market.
It insisted that such enforcement activities must be supported by verifiable evidence, professional competence and compliance with the law.
ACPN also called on the Edo State Consumer Protection Committee to disclose the identities and registration details of the products allegedly seized, alongside independent regulatory evidence establishing their status.
It maintained that pharmacies should not be publicly condemned based on unverified allegations.
The association further argued that public officials must be accountable for their statements and that regulatory powers must be exercised strictly within the limits established by law.
It vowed to defend the interests of community pharmacists and professional pharmacy practice through available institutional and legal channels.

Discussion0